Hill September 29, 2023
Joseph Choi

The deadline for drugmakers to sign agreements to negotiate with Medicare on pricing is fast approaching. Major drugmakers have until Sunday to sign an agreement to participate in the program or potentially face heavy taxes and lose their ability to sell through Medicare.

With courts yet to impose an injunction in a spate of pending lawsuits, several of the companies producing the 10 drugs selected for Medicare negotiations appear ready to move ahead with negotiations.

Merck, whose diabetes treatment Januvia was selected, made it known it will sign an agreement with the Centers for Medicare & Medicaid Services (CMS) “under protest.”

“While we disagree on both legal and policy grounds with the IRA’s new program, withdrawing all of the company’s...

Today's Sponsors


Today's Sponsor


Topics: Biotechnology, CMS, Govt Agencies, HHS, Insurance, Medicare, Pharma, Pharma / Biotech
Biotech venture firms continue ‘recalibration’ in third quarter, Pitchbook report finds
Forbes names 30 under 30 in healthcare
Insilico Medicine Launches First-in-Human Trial for AI-Discovered IBD Drug
How to Choose the Right Distribution Partner
Listen: CRISPR history, biotech struggles, & a big week for deals

Share This Article